Anti-HMW Kininogen Heavy Chain 抗体 [2B5] (ab1005)

製品の概要

  • 製品名Anti-HMW Kininogen Heavy Chain antibody [2B5]
  • 製品の詳細
    Mouse monoclonal [2B5] to HMW Kininogen Heavy Chain
  • 特異性This antibody reacts with the common heavy chain.
  • アプリケーション適用あり: ICC/IF, Coagulation, ELISA, Neutralising, WBmore details
  • 種交差性
    交差種: Human
  • 免疫原

    Purified high molecular weight kininogen (HMWK).

  • ポジティブ・コントロール
    • Normal human plasma.

製品の特性

アプリケーション

Our Abpromise guarantee covers the use of ab1005 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
ICC/IF Use at an assay dependent dilution. PubMed: 19254919
Coagulation Use at an assay dependent dilution.
ELISA Use a concentration of 5 - 10 µg/ml.
Neutralising Use at an assay dependent dilution. Neutralizes the inhibitory activity of HMWK on platelet calpain.
WB Use a concentration of 3 - 5 µg/ml.

ターゲット情報

  • 機能(1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.
  • 組織特異性Secreted in plasma. T-kinin is detected in malignant ovarian, colon and breast carcinomas, but not in benign tumors.
  • 関連疾患High molecular weight kininogen deficiency
  • 配列類似性Contains 3 cystatin kininogen-type domains.
  • 翻訳後修飾Bradykinin is released from kininogen by plasma kallikrein.
    Hydroxylation of Pro-383 occurs prior to the release of bradykinin.
    Phosphorylated by FAM20C in the extracellular medium.
    N- and O-glycosylated. O-glycosylated with core 1 or possibly core 8 glycans.
  • 細胞内局在Secreted, extracellular space.
  • Information by UniProt
  • 参照データベース
  • 別名
    • Alpha-2-thiol proteinase inhibitor antibody
    • Fitzgerald factor antibody
    • High molecular weight kininogen antibody
    • HMWK antibody
    • HMWK heavy chain antibody
    • Ile-Ser-Bradykinin antibody
    • Kallidin I antibody
    • Kallidin II antibody
    • Kininogen 1 antibody
    • Kininogen 1 heavy chain antibody
    • KNG antibody
    • KNG1 antibody
    • KNG1_HUMAN antibody
    • Low molecular weight growth-promoting factor antibody
    • Williams-Fitzgerald-Flaujeac factor antibody
    see all

Anti-HMW Kininogen Heavy Chain antibody [2B5] (ab1005) 使用論文

This product has been referenced in:
  • Cassim B  et al. Kallikreins, kininogens and kinin receptors on circulating and synovial fluid neutrophils: role in kinin generation in rheumatoid arthritis. Rheumatology (Oxford) 48:490-6 (2009). ICC/IF ; Human . Read more (PubMed: 19254919) »
  • Rocchetti MT  et al. Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy. Proteomics 8:206-16 (2008). Read more (PubMed: 18095357) »

See all 3 Publications for this product

Product Wall

Thank you for your enquiry. I am sorry you are experiencing problems with this antibody and that you did not receive the full amount in the vial. Before we replace the vial we would like to see if we can improve your results. Below please find ...

Read More

Thank you for your enquiry. I have been in touch with the source of this antibody and unfortunately this antibody does not distinguish between high molecular weight and low molecular weight kininogen. Although the epitope for this antibody has not ...

Read More

Thank you for your enquiry. I cannot recommend one specific antibody over the other. In both cases the difference is that they are different clones. The antibodies work in the same applications but the clone is different. These antibodies will re...

Read More

Thank you for your enquiry regarding ab1005 and your interest in our products. The concentration of our current lot of this antibody is 1.3 mg/ml. Dilutions for ELISA and Western blotting depend, of course, on the sample being tested. In our lab, f...

Read More

The sample was normal human plasma. Specificity was confirmed in parallel with HMWK-deficient plasma. If you have any additional questions, please contact us again.

In response to your telephone call regarding the shortage for ab1005 (you received 10ul), I have arranged for a free of charge replacement to be sent to you, which should arrive later this week. I apologize for the inconvenience and good luck in your ...

Read More

I had a chat with our Chief Scientists and they also recommended that you could try the following: · An absence of primary antibody control could be performed: run a western blot without a primary antibody and then probe with only the secon...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"